Klaus Veitinger, M.D., Ph.D.
Chief Executive Officer
Klaus Veitinger, M.D., Ph.D., is CEO of Promentis and is currently a Venture Partner with OrbiMed. During his prior 16-year pharmaceutical career, Dr. Veitinger held senior management positions in drug development, licensing and business development, strategic planning and M&A, as well as general management. Most recently Dr. Veitinger was a Member of the Executive Board of Schwarz Pharma AG and the Chief Executive Officer of Schwarz Pharma Inc. with responsibility for the U.S. and Asia businesses culminating in the ultimate sale of the Schwarz Group. Dr. Veitinger has served and currently serves on the boards of several private and public companies in the life sciences sector. For seven years he was a Director of PhRMA. Dr. Veitinger received his M.D. and his Ph.D. from the University of Heidelberg. He earned his M.B.A. at INSEAD in France.
Thomas R. Beck, M.D.
Chief Medical Officer
Tom Beck M.D., is the Chief Medical Officer of Promentis and is an Executive Partner at F-Prime Capital. Tom joined F-Prime as an Executive Partner in September 2007. Most recently he served as President, Chief Operating Officer at Dyax Corp. Prior to that, he held positions at UCB Pharma (Corporate Vice President, Director of Global Research and Development), CytoMed, Inc. (Chairman and Chief Executive Officer), and Enzytech, Inc. (President). He began his industry career at Smith Kline and French, where he held positions in both clinical development and business development.
Dr. Beck is Board-certified in Internal Medicine and Nephrology and was Assistant Professor of Medicine at Temple University School of Medicine prior to joining the pharmaceutical industry. He received his B.S. degree from Yale University and his M.D. from Cornell University.
Since joining F-Prime Capital, Dr. Beck has been on the boards of NeuroTherapeutics Pharma, Topaz Pharmaceuticals, Vicept Therapeutics, and Dimension Therapeutics. He is currently on the boards of Mersana Therapeutics, Adagene, Ltd., Symbiomix Therapeutics, and Akriveia Therapeutics. He has been CEO of Topaz Pharmaceuticals and Dimension Therapeutics, and currently is Head, Research and Development at Symbiomix.
Daniel Lawton is the President of Promentis Pharmaceuticals. Mr. Lawton has more than 20 years of experience in the pharmaceutical and life sciences industry. Previously, Mr. Lawton was Group President at Dohmen Life Sciences, and Vice President and General Counsel of Schwarz Pharma, Inc. where he was also a member of the U.S. senior management group. His previous work experience includes a number of senior positions at Abbott Laboratories supporting its U.S., Canadian, European and Japanese businesses, with a focus on new business development, licensing, acquisitions and related transactions. Mr. Lawton has practiced law at firms in Europe and the United States. He is a graduate of Harvard Law School and was a Teaching Fellow at Harvard University (Economics under Professor Martin Feldstein).
Chad E. Beyer, Ph.D., MBA
Senior Vice President of Research and Development
Chad Beyer is Senior Vice President of Research and Development at Promentis. He has over 20 years of experience in the research, discovery and business development of medications aimed to treat CNS and neurological disorders. Prior to joining Promentis, Dr. Beyer served as the Head of Neurochemistry and led the Psychiatry Task Force at Wyeth Pharmaceuticals in Princeton, NJ. During his career at Wyeth, Dr. Beyer led several early-stage drug discovery teams and managed a group responsible for contributing to the commercialization and life-cycle management of two blockbuster medications: Effexor® and Pristiq®. Dr. Beyer holds a Ph.D. in Neuropharmacology from LSU Medical Center and an MBA from the Rutgers Business School. Notably, Dr. Beyer has authored more than 70 manuscripts, 3 patents, co-edited “Next Generation Antidepressants” and is co-founder of the journal “Technology Transfer & Entrepreneurship.” Dr. Beyer is also an adjunct faculty member at Thomas Jefferson University in Philadelphia where he teaches “Bioventure Management”, a class focused on the business of doing science.
Michael P. Neary, B.S.
Director of Research
Michael Neary is currently Director of Research at Promentis. Since beginning work at Promentis in 2010, Mr. Neary has taken on an increasingly important role within the company; he now oversees the Promentis day-to-day research efforts, coordinates the activities of Promentis’ collaborators, and continues to work toward advancing Promentis’ scientific platform and lead molecules closer to the patients who suffer from these devastating disorders. Prior to joining Promentis, Mr. Neary worked at Roche Madison on programs focused on the development of RNAi delivery platforms. Mr. Neary holds a Biochemistry degree from the University of Wisconsin (Madison).
Financial and Accounting Advisor
Stacy Holland is currently the financial and accounting advisor for the operations of Promentis Pharmaceuticals. She most recently served as chief financial officer for a multi-national subsidiary of Dover Corporation with responsibility for the Company’s financial matters, regulatory compliance, and information technology services. She previously held auditing, accounting and management positions at Deloitte LLC, Rockwell Automation and Briggs and Stratton.
Stacy is a Certified Public Accountant and graduate of the University of Wisconsin-Milwaukee where she received her Bachelor’s degree in Accounting.
Pioneering the discovery & development of therapeutics targeting glutamatergic imbalances and oxidative stress